Kurse werden geladen...
Prognose
| Kaufen |
1 |
| Halten |
0
|
| Verkaufen |
0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
14.03. - 11:00 Uhr
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences: Stifel 2024 Virtual CNS Days Format: Fireside Chat Date: Wednesday, March 20 at 8:00 a.m. ET Cantor Virtual Muscular Dystrophy Symposiu. » Mehr auf businesswire.com
20.09. - 11:00 Uhr
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New York City. Mr. Frank Gleeson, President and CEO of Satellos, will participate in a panel presentation on Wednesday, September 27, 2023, at 2:25 p.m. » Mehr auf newsfilecorp.com
17.03. - 11:00 Uhr
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced that Ryan Mitchell, PhD and Director of Business Development will present preclinical proof of concept data the Company has generated with its lead drug candidate SAT-3153. These data will be featured in a poster presentation at this year's Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held in Dallas, TX from March 19-23, 2023. » Mehr auf newsfilecorp.com
Unternehmenszahlen
| (EUR) | März 2024 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | 4,73 Mio | 317,92% |
| EBITDA | 5,35 Mio | 374,77% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 37,35 Mio € |
Anzahl Aktien | 112,79 Mio |
52 Wochen-Hoch/Tief | 0,53 € - 0,20 € |
| Dividenden | Nein |
Beta | 1,15 |
KGV (PE Ratio) | 4,35 |
KGWV (PEG Ratio) | 0,10 |
KBV (PB Ratio) | 1,63 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Satellos Bioscience Inc. ist ein Unternehmen für regenerative Medizin und entwickelt Therapeutika zur Behandlung degenerativer Muskelkrankheiten. Das Hauptprogramm des Unternehmens konzentriert sich auf die Entwicklung eines oralen therapeutischen Medikaments zur Korrektur der Polarität von Muskelstammzellen und zur Wiederherstellung des körpereigenen Muskelreparatur- und Regenerationsprozesses. Das Unternehmen wurde 2012 gegründet und hat seinen Hauptsitz in Toronto, Kanada.
| Name | Satellos Bioscience |
| CEO | Francis Gleeson B.B.A. M.B.A |
| Sitz | Toronto,
on Kanada |
| Website | |
| Börsengang | 07.01.2008 |
| Mitarbeiter | 3 |
Ticker Symbole
| Börse | Symbol |
|---|---|
Pnk | MSCLF |
Tsxv | MSCL.V |
Frankfurt | 0ITA.F |
Assets entdecken
Shareholder von Satellos Bioscience investieren auch in folgende Assets
